Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma
Blood Cancer Talks
00:00
The Differences Between CARMA 3 and CARTUT4
In CARMA 3, the control arm was a little bit more ingenious. It was pretty much ciltacil versus darapomb-dex-trial. Do you think if daracadia or isa-kady was in the control arm, some of the benefit of CART would have been attenuated? I mean, that's a little bit hard to speculate. But your point is well taken.
Transcript
Play full episode
